<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/A69BD168-A5D3-4FD0-A7F0-0287C8A3F1D6"><gtr:id>A69BD168-A5D3-4FD0-A7F0-0287C8A3F1D6</gtr:id><gtr:name>Ai2 Ltd</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>G-Floor The Mill</gtr:line1><gtr:line2>University of Manchester</gtr:line2><gtr:line3>Sackville Street</gtr:line3><gtr:line4>Manchester</gtr:line4><gtr:postCode>M60 1QD</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A69BD168-A5D3-4FD0-A7F0-0287C8A3F1D6"><gtr:id>A69BD168-A5D3-4FD0-A7F0-0287C8A3F1D6</gtr:id><gtr:name>Ai2 Ltd</gtr:name><gtr:address><gtr:line1>G-Floor The Mill</gtr:line1><gtr:line2>University of Manchester</gtr:line2><gtr:line3>Sackville Street</gtr:line3><gtr:line4>Manchester</gtr:line4><gtr:postCode>M60 1QD</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6AE160F9-19FE-4B58-8CFB-59304C67AEF9"><gtr:id>6AE160F9-19FE-4B58-8CFB-59304C67AEF9</gtr:id><gtr:firstName>Curtis</gtr:firstName><gtr:surname>Dobson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FD525148%2F1"><gtr:id>8E0BDBD4-206A-4AD3-896E-FBB6DC9AE7C9</gtr:id><gtr:title>Development of a novel contact lens coating into an antibacterial technology platform for use with medical devices.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D525148/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2008-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>219435</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>833333</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Further investment into grant-holding organisation (Ai2 Ltd.)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>MTI Ventures</gtr:fundingOrg><gtr:id>0E4B9187-A4F3-477C-B4F7-917835183345</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>833333</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Further investment into grant-holding organisation (Ai2 Ltd.)</gtr:description><gtr:fundingOrg>University of Manchester Intellectual Property</gtr:fundingOrg><gtr:id>945B4983-71B8-4806-A5C5-47419B78632D</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>833333</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Further investment into grant-holding organisation (Ai2 Ltd.)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>MTI Ventures</gtr:fundingOrg><gtr:id>E0769C34-4C94-47FE-8793-C9AB660E93A6</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>833333</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Further investment into grant-holding organisation (Ai2 Ltd.)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Spark Ventures</gtr:fundingOrg><gtr:id>7EA0738D-3546-45D4-8770-FC9B557CEDF4</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>833333</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Further investment into grant-holding organisation (Ai2 Ltd.)</gtr:description><gtr:fundingOrg>Spark Ventures</gtr:fundingOrg><gtr:id>20A971D6-46F6-4F84-904F-AD7451898725</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2009-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Used to support the development of a novel family of protein biocides by Ai2 Ltd. a University of Manchester spin-out company. These are being developed for use in ophthalmic applications.</gtr:description><gtr:firstYearOfImpact>2010</gtr:firstYearOfImpact><gtr:id>E62D4A3D-8BD8-4735-B215-1B2F42B2CAEA</gtr:id><gtr:impactTypes><gtr:impactType>Societal,Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Novel antimicrobial peptides</gtr:description><gtr:id>10B6C48A-40D9-4E69-A81C-D50BDB114D29</gtr:id><gtr:impact>Spin-out company employing 10 FTEs operating for 10 years</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>WO2005061539</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment of Viral Infection</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>We engineered an anti-infective human protein sequence to stick to different polymers, and provide an antimicrobial surface to prevent medical device infection.</gtr:description><gtr:exploitationPathways>The findings defined a new class of antimicrobial coating, which is being developed by a spin-out company (Ai2 Ltd.) to reduce rates of medical device infection, in collaboration with other larger healthcare corporations.</gtr:exploitationPathways><gtr:id>07AD87EF-B82C-423E-9865-97C8166135B2</gtr:id><gtr:sectors><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.bbsrc.ac.uk/research/impact/smart-coatings-sensors-guard-against-infection/</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Ai2 Ltd.</gtr:companyName><gtr:description>Ai2 Ltd is a UK-based biotechnology company that specialises in novel anti-infective peptide technology which combines potent efficacy with excellent safety. Ai2 is developing this technology for a variety of applications in healthcare and personal care areas where this combination of safety and efficacy can provide significant benefits.</gtr:description><gtr:id>77396FF6-A2ED-4C45-B5EA-AE45029F180F</gtr:id><gtr:impact>Major License Deal with Sauflon Pharmaceuticals in 2010</gtr:impact><gtr:url>http://www.a-i-2.com</gtr:url><gtr:yearCompanyFormed>2005</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/52A6F11E-AEDA-4692-B60E-7236945BAF8C"><gtr:id>52A6F11E-AEDA-4692-B60E-7236945BAF8C</gtr:id><gtr:title>Comparative surface antimicrobial properties of synthetic biocides and novel human apolipoprotein E derived antimicrobial peptides.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d4317d8bceff2587c17644c5586864a"><gtr:id>8d4317d8bceff2587c17644c5586864a</gtr:id><gtr:otherNames>Forbes S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/D525148/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>